Following on from LVPEI’s successful proof of concept studies highlighting the successful use of Atelerix’s technology to distribute a limbal-stromal cell therapy throughout India (Damala et al., 2019), we are delighted to announce the publication of subsequent preclinical studies. These studies demonstrate the safety and efficacy of the therapy after being encapsulated and stored at room temperature, used to support the successful acceptance of an ongoing Phase 1 clinical trial (Clinical Trial ref. CTRI/2021/07/035034). It is hoped that this clinical trial will demonstrate how our technology can be utilised to increase the accessibility of advanced therapies in India to treat debilitating conditions such as corneal pathologies and blindness.

You can access the full publication HERE